ESR Essentials: staging and restaging with FDG-PET/CT in oncology—practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging - Top-Institutions - MDSpire

ESR Essentials: staging and restaging with FDG-PET/CT in oncology—practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging

  • By

  • Ricarda Ebner

  • Gabriel T. Sheikh

  • Matthias Brendel

  • Jens Ricke

  • Clemens C. Cyran

  • October 9, 2024

  • 0 min

Share

Top Institutions in Radiology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Molecular Imaging
    • Nuclear Medicine

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Radiology
    • Nuclear Medicine

  • #3

    European Institute of Oncology (IEO)
    European Institute of Oncology (IEO)

    Milan, Lombardy

    Key Differentiators

    • Oncology
    • Nuclear Medicine
    • Molecular Imaging

  • #4

    National Cancer Institute (NCI) - NIH
    National Cancer Institute (NCI) - NIH

    Bethesda, MD

    Key Differentiators

    • Cancer Research
    • Molecular Imaging
    • Nuclear Medicine

  • #5

    University of Heidelberg - Department of Nuclear Medicine
    University of Heidelberg - Department of Nuclear Medicine

    Heidelberg, Baden-Württemberg

    Key Differentiators

    • Nuclear Medicine
    • Oncology
    • Molecular Imaging

Original Source(s)

ESR Essentials: staging and restaging with FDG-PET/CT in oncology—practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging

  • by Ricarda Ebner, Gabriel T. Sheikh, Matthias Brendel, Jens Ricke, Clemens C. Cyran

  • October 9, 2024

Related Content

Comprehensive Evaluation of Biological Age Post-Radiation Therapy in Early-Stage Non-Small Cell Lung Cancer Patients

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.

Comparing the detectability of pulmonary nodules on two ultra-high resolution CT scanners: a preliminary phantom study